Cancer diagnostics using epigenetic markers

Fast, reliable, and non-invasive cancer diagnostics

 Scroll down ⇩

Cancer diagnostics 

DNA methylation

Pipeline / Contact

GynTect®

Download Flyer: GynTect®

 Cancer diagnostics using epigenetic markers

The biotech company oncgnostics focuses on the development of cancer diagnostics. In all tests developed by oncgnostics epigenetic changes, so-called DNA methylation, characteristic for cancer cells are detected. These highly informative markers, identified and validated by oncgnostics, constitute the core of the technology.


First product: GynTect®


The clarification test GynTect® is used in the early detection of cervical cancer and its precursors. Furthermore, the German biotech company develops tests for the medical fields head and neck tumours and ovarian cancer.

DNA METHYLATION ▼

 DNA methylation in cervical cancer diagnostics

In the course of cervical carcinogenesis alterations occur in genomic regions. One of them is the hypermethylation of certain DNA regions. The diagnostic test GynTect® allows the detection of DNA hypermethylation of six DNA regions in the human genome specifically occurring in cervical carcinogenesis.


Performance of GynTect® requires a cervical smear. The marker regions are detected by PCR (polymerase chain reaction). The data obtained provide the basis for the GynTect® result. Originally methylated marker DNA regions are amplified in the marker PCRs only. Therefore the method is also called methylation-specific PCR.

PIPELINE / CONTACT ▼

Pipeline: Diagnostics in head & neck tumours and ovarian cancer

Oncgnostics currently validates epigenetic markers for the development of diagnostics for use in other cancers.


Diagnostics available in the field of head and neck tumours are currently very limited. Tumours are only detected when they become macroscopically visible. Therefore the chances of a cure are limited. A test for early detection based on the epigenetic markers validated by oncgnostics could contribute to improve the chances for a full cure. Furthermore, the frequent relapses occurring after removal of a tumour may be detected and treated earlier.


Moreover, oncgnostics works, in close collaboration with the University Hospital Jena, in the development of ovarian cancer diagnostic tests.

Contact:

Oncgnostics GmbH
Winzerlaer Straße 2
07745 Jena
Germany


www.oncgnostics.com

contact@oncgnostics.com

+49 3641 55485 00

BACK TO TOP ▲

Go to article: Home | Becoming the first human cyborgGo to article: In this issueGo to article: ContentsGo to article: Formacoat Company InsightGo to article: FormacoatGo to article: uvexGo to article: BriefingGo to article: Industry newsGo to article: Covid-19 executive briefing by GlobalDataGo to article: The medical industry briefingGo to article: Industrial Indexing Systems Company InsightGo to article: Industrial Indexing SystemsGo to article: ElectroCraftGo to article: KSP Go to article: Electronic Sensor TechnologyGo to article: CommentGo to article: Robotics in medtech industry primed for significant growth to end bumpy 2020Go to article: AI-powered platforms expand further into traditional healthcareGo to article: Penumbra’s Indigo Aspiration System expected to continue dominating US marketGo to article: Early on, 5G is already making an impact and demonstrating its potentialGo to article: ENT market on course for full recovery following year disrupted by Covid-19Go to article: Research Collective Company Insight Go to article: Research CollectiveGo to article: Repsol Go to article: SartoriusGo to article: Peak Performance Compounding Go to article: In DepthGo to article: The ins and outs of the SABA asthma inhalerGo to article: Can you hear me now? The tech transforming clinical communicationGo to article: Should biobanks release diagnostic data to patients?Go to article: Inside the mission to become the first cyborgGo to article: Miracle metal: could copper clothing help fight infection?Go to article: LexaGene’s new automated testing platformGo to article: Recurrent fainting: could a new pacemaker provide a solution?Go to article: Kickstarting AI and smart data in resource-limited health systemsGo to article: BioInteractions Company Insight Go to article: BioInteractions Go to article: Sandvik Company InsightGo to article: Sandvik Go to article: ICF MercantileGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The medical industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: Fisba Go to article: INDO-MIMGo to article: AccumoldGo to article: GS SwissGo to article: oncgnosticsGo to article: EventsGo to article: Next issueGo to article: CODIXX Go to article: Alicona ImagingGo to article: RETERO Go to article: CoherentGo to article: Eastprint Incorporated